文献速递传染病防控与疫情报告免疫规划

印第安纳州四所大学的腮腺炎暴发,2016年

Mumps Outbreaks at Four Universities - Indiana, 2016.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2018-07-27

2016年2月至4月,印第安纳州卫生部确认四所大学发生腮腺炎暴发,281例确诊和可能病例中216例(76.9%)有推定性免疫证据。部分大学难以核实2剂MMR接种记录,实施排除易感者政策困难;实验室检测方案提高了标本阳性率和病例发现。2018年ACIP建议暴发中高风险人群接种第三剂MMR。

要点

  • 281例确诊和可能病例中216例(76.9%)有推定性免疫证据。
  • 部分大学无法获得2剂MMR接种记录,核实耗费大量人力。
  • 实验室检测方案提高了标本阳性百分比并改善病例发现。

核心结论

  • 针对腮腺炎确认的标本采集和标准化疫苗接种记录的特殊实验室检测指导可 aid 暴发管理。
  • 对排除政策的评估可能也是必要的。

研究设计与样本

  • 2016年2月至4月,印第安纳州卫生部确认四所大学(三所公立、一所私立)发生腮腺炎暴发,所有大学位于印第安纳波利斯65英里范围内,但暴发间流行病学联系有限。
  • ISDH和地方卫生部门调查暴发并在所有大学启动控制措施。
  • 制定并分发描述推荐腮腺炎检测、暴发期间检测优先级和向ISDH实验室提交标本预授权流程的方案。
  • 每所大学暴发在未发现病例经过两个潜伏期后宣布结束;最后一起暴发于2016年9月10日结束。

主要发现

  • 共识别281例确诊和可能病例,其中216例(76.9%)有推定性免疫证据的文件记录。
  • 部分大学无法获得2剂MMR接种记录(免疫证据标准之一),核实需要大量人员时间。
  • 实施将易感者排除在课堂和其他群体环境之外的政策也困难。
  • 实验室检测方案提高了标本检测阳性百分比并改善病例发现。

关键数值与推荐

  • 2018年,免疫实践咨询委员会(ACIP)发布推荐:此前接种过2剂MMR、被公共卫生当局确定为腮腺炎暴发期间感染风险增加群体成员的人接种第三剂MMR。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

From February to April 2016, the Indiana State Department of Health (ISDH) confirmed mumps outbreaks at four universities (three public and one private). All universities were located within 65 miles of Indianapolis; however, epidemiologic links among outbreaks were limited. ISDH and local health departments investigated the outbreaks and initiated control measures at all universities. A protocol describing recommended testing for mumps, testing priorities during the outbreak, and a preauthorization process for submitting specimens to the ISDH Laboratory (ISDHL) was developed and disseminated to providers and public health partners (1). Outbreaks at each university were declared over after two incubation periods* elapsed without identified cases; the last outbreak ended September 10, 2016. Among the 281 confirmed and probable cases identified, 216 (76.9%) persons had documentation of presumptive evidence of immunity† (2). At some universities, documentation of receipt of 2 doses of measles, mumps, rubella vaccine (MMR), which is a criterion for evidence of immunity, was not available and required substantial personnel time to verify. Implementation of policies for excluding susceptible persons from classes and other group settings was also difficult. The laboratory testing protocol increased the percentage of specimens testing positive and improved case detection. Outbreak-specific laboratory testing guidance on specimen collection for mumps confirmation and standardized vaccination documentation in highly vaccinated settings could aid outbreak management. Evaluation of exclusion policies might also be necessary. In 2018, the Advisory Committee on Immunization Practices (ACIP) published a recommendation that persons previously vaccinated with 2 doses of MMR who are determined by public health authorities to be part of a group at increased risk for infection during a mumps outbreak receive a third dose of MMR (3).

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Golwalkar M, Pope B, Stauffer J, et al. Mumps Outbreaks at Four Universities - Indiana, 2016. MMWR Morb Mortal Wkly Rep. 2018. PMID: 30048422. doi:10.15585/mmwr.mm6729a1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。